GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hyundai Pharmaceutical Co 004310.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

6,120

0.00%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩191.79bn

FY2016FY2025

Net income

₩2.52bn

FY2016FY2025

Free cash flow

−₩5.99bn

FY2016FY2025

Shareholders' equity

₩82.10bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩191.79bn₩175.74bn₩180.76bn₩162.69bn₩139.80bn₩132.97bn₩134.92bn₩133.94bn₩130.48bn₩120.02bn
Gross profit₩79.60bn₩73.37bn₩76.59bn₩68.84bn₩56.31bn₩58.32bn₩63.86bn₩63.64bn₩61.98bn₩47.14bn
Research and development₩17.71bn₩15.33bn₩12.23bn₩8.38bn₩8.09bn₩9.62bn₩12.47bn₩13.49bn₩13.13bn₩6.0m
Operating income₩4.16bn₩180.9m₩6.93bn₩7.97bn−₩1.57bn₩3.05bn₩1.56bn₩1.22bn₩2.01bn₩2.33bn
Net income₩2.52bn−₩574.9m₩6.12bn−₩164.6m−₩3.17bn₩2.19bn₩1.16bn₩928.9m₩1.46bn₩1.26bn
Diluted earnings per share93.23-21.30226.81-6.10-117.5781.0342.9234.4254.0346.72

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩163.22bn₩156.40bn₩154.63bn₩181.16bn₩163.86bn₩157.50bn₩145.47bn₩158.80bn₩154.62bn₩150.55bn
Total liabilities₩81.11bn₩77.32bn₩69.97bn₩94.60bn₩77.26bn₩67.36bn₩57.89bn₩51.80bn₩56.52bn₩50.47bn
Debt₩5.66bn₩14.67bn—₩10.00bn₩15.00bn—₩21.00bn₩21.00bn₩29.45bn₩26.94bn
Shareholders' equity₩82.10bn₩79.07bn₩84.66bn₩86.56bn₩86.60bn₩90.14bn₩87.58bn₩107.00bn₩98.10bn₩100.08bn
Shares outstanding27m27m27m27m27m27m27m27m27m27m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩123.3m−₩2.37bn−₩4.55bn₩11.62bn₩5.13bn₩10.80bn₩6.96bn₩2.83bn−₩1.98bn−₩2.75bn
Capital spending−₩5.86bn−₩11.18bn−₩6.10bn−₩6.58bn−₩6.81bn−₩6.40bn−₩2.36bn−₩2.67bn−₩3.10bn−₩3.68bn
Free cash flow−₩5.99bn−₩13.56bn−₩10.65bn₩5.04bn−₩1.68bn₩4.40bn₩4.60bn₩168.1m−₩5.08bn−₩6.43bn
Dividends paid−₩783.7m−₩923.1m−₩826.2m−₩836.1m−₩1.18bn−₩1.21bn−₩1.23bn−₩1.18bn−₩1.15bn−₩1.16bn

Latest quarters

By quarter end

Aug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024
Revenue₩56.27bn₩55.59bn₩46.45bn₩48.72bn₩51.57bn₩48.41bn₩43.09bn₩42.86bn
Gross profit₩22.05bn₩21.08bn₩19.86bn₩19.74bn₩20.87bn₩20.90bn₩18.10bn₩16.86bn
Operating income₩2.44bn₩976.3m₩2.52bn₩42.7m₩3.46bn₩1.08bn−₩414.7m−₩2.00bn
Net income₩1.71bn₩1.21bn₩420.0m₩268.2m₩2.54bn₩956.5m−₩985.3m−₩1.48bn
Diluted earnings per share63.4044.9015.569.9497.3535.44-36.50-54.78
Cash from operations₩5.86bn₩2.39bn₩188.0m₩1.83bn−₩1.19bn−₩2.99bn₩2.23bn₩679.0m
Capital spending−₩1.38bn−₩1.09bn−₩2.59bn−₩1.63bn−₩838.0m−₩1.59bn−₩1.80bn−₩2.17bn
Free cash flow₩4.48bn₩1.30bn−₩2.40bn₩196.0m−₩2.03bn−₩4.59bn₩435.0m−₩1.49bn
Total assets₩227.47bn₩224.69bn₩224.31bn₩163.22bn₩163.07bn₩163.39bn₩158.29bn₩156.40bn
Cash and short-term investments————₩2.35bn———
Debt₩26.45bn₩26.68bn₩5.43bn₩5.66bn₩47.49bn₩4.67bn₩14.67bn₩14.67bn
Shareholders' equity₩129.12bn₩128.05bn₩134.81bn₩82.10bn₩79.78bn₩77.99bn₩77.71bn₩79.07bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.6%7.6%5.7%
Operating income-19.5%6.4%9.3%
Net income—2.8%4.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin41.6%42.0%42.0%42.9%
Operating margin1.2%2.7%2.1%1.8%
Net margin0.5%1.1%0.7%0.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings91.4-168.318.1-785.5-50.695.3121.9137.070.2101.5
Price to sales1.20.60.60.81.11.61.10.90.81.1

Dividends and splits

Per share, in the currency the company pays

Paid for 2 years. Last went ex-dividend on 3 Mar 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year30.0030.0035.0030.0030.0042.5045.0045.00
  • 10-for-1 split · 28 Mar 2008
  • 1.039-for-1 split · 29 Nov 2000
  • 1.03-for-1 split · 29 Nov 1999
  • 1.099-for-1 split · 17 Jun 1999
  • 1.032-for-1 split · 28 Nov 1998
  • 11-for-10 split · 16 Jun 1998

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.